Proshares Trust ZBIO
ZBIO
$28.83 +0.75 (+2.67%)
As of: Oct 22, 2026 · 9:39 AM EDT

Zenas BioPharma (ZBIO) Convertible Debt (2023)

Updated

Zenas BioPharma's Convertible Debt came in at $20.3 million for Q4 2023.

Analysis

Zenas BioPharma (ZBIO) Convertible Debt (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,155.80 Bn 1,124.39 Bn 19.71 Bn
2 Johnson & Johnson 630.65 Bn 549.18 Bn 17.26 Bn
3 AbbVie 502.74 Bn 475.85 Bn 12.70 Bn
4 Merck 375.34 Bn 329.72 Bn 12.21 Bn
5 Novartis Ag 301.36 Bn 265.35 Bn 11.24 Bn
6 Astrazeneca 265.02 Bn 238.70 Bn 12.86 Bn
7 Amgen 239.16 Bn 194.55 Bn 7.24 Bn
8 Gilead Sciences 192.63 Bn 166.82 Bn 6.22 Bn
9 Pfizer 171.82 Bn 118.47 Bn 10.94 Bn
10 Zenas BioPharma 1.82 Bn 1.15 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 20.30 Mn
API Access

Zenas BioPharma Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ZBIO&period=max&api_key=YOUR_API_KEY